Alefacept

Generic Name: Alefacept

Drug Type: Biotech

CAS Number: 222535-22-0

Unique Ingredient Identifier: ELK3V90G6C

Background: Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.

Indication: As an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasis

Clinical Trials

Assessment and Tracking of Long-term Alefacept Safety

Terminated

Conditions: Psoriasis

Interventions: Drug: Alefacept exposure

First Posted Date: 2007-04-02

Last Posted Date: 2013-12-11

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 1897

Registration Number: NCT00454701

Locations: 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸
Georgia Skin Specialists, Atlanta, Georgia, United States
🇺🇸
Advanced Dermatology, Fresh Meadows, New York, United States

and more 260 locations

Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: Alefacept

First Posted Date: 2007-02-22

Last Posted Date: 2019-08-13

Lead Sponsor: Mayo Clinic

Target Recruit Count: 23

Registration Number: NCT00438802

Locations: 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States

Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan Patients

Not Applicable

Completed

Conditions: Chronic Plaque Psoriasis

First Posted Date: 2007-01-17

Last Posted Date: 2007-01-17

Lead Sponsor: Uni-Pharma

Target Recruit Count: 40

Registration Number: NCT00422617

Alefacept (Amevive) With or Without Narrowband UVB Treatment in Patients With Psoriasis.

Not Applicable

Completed

Conditions: Psoriasis

First Posted Date: 2006-12-05

Last Posted Date: 2009-09-30

Lead Sponsor: Medical University of Graz

Target Recruit Count: 14

Registration Number: NCT00407342

Locations: 🇦🇹
Medical University of Graz, Graz, Styria, Austria

Alefacept for Chronic Graft Versus Host Disease

Phase 1

Completed

Conditions: Resistant Chronic GVHD

First Posted Date: 2006-11-09

Last Posted Date: 2015-04-21

Lead Sponsor: Hadassah Medical Organization

Target Recruit Count: 20

Registration Number: NCT00397332

Locations: 🇮🇱
Department of Stem cell Transplantation & Cancer immunotherapy; Cell Therapy & Transplantation Biology Research Laboratory, Hadassah University Hospital, Jerusalem, Israel

Open-Label,Singel Center Study of Alefacept in Patients With Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Alefacept

First Posted Date: 2006-09-14

Last Posted Date: 2007-12-10

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 10

Registration Number: NCT00376129

Locations: 🇨🇭
Inselspital Dermatology, Bern, Switzerland

Alefacept for Prevention of Graft Versus Host Disease (GVHD)

Phase 3

Terminated

Conditions: Graft Versus Host Disease

Interventions: Drug: control group
Drug: Alefacept (AMEVIVE®)

First Posted Date: 2006-08-08

Last Posted Date: 2015-04-21

Lead Sponsor: Hadassah Medical Organization

Target Recruit Count: 26

Registration Number: NCT00361413

Locations: 🇮🇱
Department of Stem Cell Transplantation & Cancer Immunotherapy, Jerusalem, Israel

Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar Pustulosis

Phase 2

Completed

Conditions: Psoriasis
Palmoplantaris Pustulosis
Pustular Psoriasis of Palms and Soles
Pustulosis Palmaris et Plantaris
Pustulosis of Palms and Soles

First Posted Date: 2006-03-10

Last Posted Date: 2006-11-23

Lead Sponsor: The Guenther Dermatology Research Centre

Target Recruit Count: 15

Registration Number: NCT00301002

Locations: 🇨🇦
The Guenther Dermatology Research Centre, London, Ontario, Canada

Safety and Tolerability of Repeat Courses of IM Alefacept

Phase 3

Completed

Conditions: Chronic Plaque Psoriasis

First Posted Date: 2005-10-06

Last Posted Date: 2023-08-23

Lead Sponsor: Biogen

Target Recruit Count: 400

Registration Number: NCT00233662

Locations: 🇨🇦
Dermatrials Research, Hamilton, Ontario, Canada
🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇫🇷
Hopital L'Archet II, Nice, France

and more 43 locations

Community Based Trial for AMEVIVE®

Phase 4

Completed

Conditions: Moderate to Severe Chronic Plaque Psoriasis

Interventions: Drug: Alefacept

First Posted Date: 2005-09-15

Last Posted Date: 2014-09-08

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 114

Registration Number: NCT00168753

Locations: 🇺🇸
Michael Scannon, Tampa, Florida, United States
🇺🇸
Calumet Dermatology Associates, Calumet City, Illinois, United States
🇺🇸
Skin and Cancer Associates, Tamarac, Florida, United States

and more 33 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy